Last reviewed · How we verify

High-dosage SARS-CoV-2 vaccine — Competitive Intelligence Brief

High-dosage SARS-CoV-2 vaccine (High-dosage SARS-CoV-2 vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated viral vaccine. Area: Immunology.

marketed inactivated viral vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

High-dosage SARS-CoV-2 vaccine (High-dosage SARS-CoV-2 vaccine) — Sinovac Biotech Co., Ltd. This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
High-dosage SARS-CoV-2 vaccine TARGET High-dosage SARS-CoV-2 vaccine Sinovac Biotech Co., Ltd marketed inactivated viral vaccine
COVAX only (1st and 2nd dose) COVAX only (1st and 2nd dose) China National Biotec Group Company Limited marketed Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens
FSME-IMMUN Vaccine FSME-IMMUN Vaccine Region Örebro County marketed Inactivated viral vaccine Tick-borne encephalitis virus (TBEV)
HAVpur Junior HAVpur Junior Crucell Holland BV marketed Inactivated viral vaccine Hepatitis A virus (HAV)
EV71 +SIV EV71 +SIV Zhejiang Provincial Center for Disease Control and Prevention marketed Inactivated viral vaccine
EV71 (inoculation vaccine) EV71 (inoculation vaccine) Shandong Province Centers for Disease Control and Prevention marketed inactivated viral vaccine Enterovirus 71 (EV71) viral antigens
Inactivated SARS-CoV-2 Vaccine (Vero cell) Inactivated SARS-CoV-2 Vaccine (Vero cell) Sinovac Research and Development Co., Ltd. marketed inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated viral vaccine class)

  1. Sinovac Biotech Co., Ltd · 5 drugs in this class
  2. Sinovac Research and Development Co., Ltd. · 2 drugs in this class
  3. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
  4. Federal University of Espirito Santo · 1 drug in this class
  5. International Vaccine Institute · 1 drug in this class
  6. MacroGenics · 1 drug in this class
  7. Shandong Province Centers for Disease Control and Prevention · 1 drug in this class
  8. Beijing Chaoyang District Centre for Disease Control and Prevention · 1 drug in this class
  9. Zhejiang Provincial Center for Disease Control and Prevention · 1 drug in this class
  10. Centers for Disease Control and Prevention · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High-dosage SARS-CoV-2 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dosage-sars-cov-2-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: